After systemic administration, V66 targets exDNA in the tumor microenvironment and enters tumor cell nuclei via the ENT2 nucleoside transporter, which is upregulated in multiple cancer types in patients compared to their matched healthy tissues (Fig. S1A), and is also elevated in mouse tumor cells relative to healthy tissues [26]. This evidence concerns the gene SLC29A2 and cancer.